Gynecologic OncologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

816 records returned

Self-reported sexual debut and behavior in young adults aged 18-24 years in seven European countries: implications for HPV vaccination programs.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: This survey provides an update on sexual debut and behavior in young adults in some European countries. Estimated age at sexual debut ranged between 16 and 18 years and appeared to be later in girls than in boys. The proportion of girls sexually active before the age of 15 years was low (</=11.9%). Almost one-third of young women did not use a condom. This survey provides useful information to support current or planned HPV vaccination programs in Europe. PMID: 19552945 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Crochard A, Luyts D, di Nicola S, Gonçalves MA Tags: Gynecol Oncol Source Type: journals

Application of a risk scoring system to predict surgical adverse events in the management of epithelial ovarian cancers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19883850 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 5, 2009 Category: Cancer & Oncology Authors: Li AJ Tags: Gynecol Oncol Source Type: journals

IDO and outcomes in ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19822256 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 14, 2009 Category: Cancer & Oncology Authors: Nelson BH Tags: Gynecol Oncol Source Type: journals

Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19822354 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Karam AK, Karlan BY Tags: Gynecol Oncol Source Type: journals

Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: We find that metformin is a potent inhibitor of cell proliferation in endometrial cancer cell lines. This effect is partially mediated through AMPK activation and subsequent inhibition of the mTOR pathway. This work should provide the scientific foundation for future investigation of metformin as a strategy for endometrial cancer prevention and treatment. PMID: 19822355 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL Tags: Gynecol Oncol Source Type: journals

Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DISCUSSION: Measurement of hyperglycosylated hCG or invasiveness is a critical step in management of invasive gestational trophoblastic disease. Quiescent of inactive gestational trophoblastic disease requires no therapy. Minimally invasive disease in chemorefractory. The USA hCG Reference Service experience suggests waiting until hCG exceeds 3000 IU/L before commencing any chemotherapy. PMID: 19822356 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Cole LA, Muller CY Tags: Gynecol Oncol Source Type: journals

Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: These data suggest LDL is a significant predictor of clinical outcome, and warrant the further study of lipoproteins and statins on epithelial ovarian cancer biology. PMID: 19822357 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Li AJ, Elmore RG, Chen IY, Karlan BY Tags: Gynecol Oncol Source Type: journals

Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: A subset of ovarian carcinoma patients with an excellent outcome can be identified based on tumor type (endometrioid or mucinous) and stage (Ia or Ib). Type is more reproducibly assigned than grade and identifies a larger cohort of women with stage I/II ovarian carcinoma with favorable outcomes (12.2% vs. 6.5%), and therefore is superior to grade in estimating risk of death from ovarian carcinoma. PMID: 19822358 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD Tags: Gynecol Oncol Source Type: journals

Should the extreme drug resistance assay fade into oblivion? Commentary on Karam, A.K., Chiang, J.W., Fung, E., Nossov, V. and Karlan, B.Y. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol. 2009;114:246-252.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19822359 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2009 Category: Cancer & Oncology Authors: Einenkel J, Wuttke P, Horn K Tags: Gynecol Oncol Source Type: journals

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The priority of routine vaccination programmes must be to target girls and young women, with catch-up programmes that extend to age 25/26 when resources allow. For sexually active women over the age of 25, HPV vaccination can be considered on an individual basis, as most will have the potential to benefit from vaccination. PMID: 19819540 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 8, 2009 Category: Cancer & Oncology Authors: Castellsagué X, Schneider A, Kaufmann AM, Bosch FX Tags: Gynecol Oncol Source Type: journals

Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: CA125 level after 6 cycles of adjuvant chemotherapy is a strong independent prognostic factor for high-risk, early stage epithelial ovarian cancer after achieving a complete response. PMID: 19818996 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 7, 2009 Category: Cancer & Oncology Authors: Kang WD, Choi HS, Kim SM Tags: Gynecol Oncol Source Type: journals

Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: AR allelotype length did not correlate with survival in this statistically representative cohort of patients with BRCA1/2 mutations. Potential associations between short AR and outcome in BRCA2-associated ovarian cancers remain to be determined. PMID: 19818997 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 7, 2009 Category: Cancer & Oncology Authors: Li AJ, McAllister P, Karlan BY Tags: Gynecol Oncol Source Type: journals

Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups. PMID: 19818481 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 6, 2009 Category: Cancer & Oncology Authors: Uberti EM, Fajardo MD, Ferreira SV, Pereira MV, Seger RC, Moreira MA, Torres MD, de Nápoli G, Schmid H Tags: Gynecol Oncol Source Type: journals

Submission of the entire lymph node dissection for histologic examination in gynecologic-oncologic specimens. Clinical and pathologic relevance.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The impact on patient outcome is minimal and it does not prove to be cost and time effective when submitting the entire LN dissection specimen in gynecologic malignancies. However, this method could be justified in selective cases in which the manual node dissection does not reveal an adequate number of LNs. PMID: 19811809 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2009 Category: Cancer & Oncology Authors: Mhawech-Fauceglia P, Herrmann FR, Wagner H, Godoy H, Odunsi K, Cheney RT, Lele S Tags: Gynecol Oncol Source Type: journals

Application of proteomics in ovarian cancer: Which sample should be used?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: To date no biomarkers for early diagnosis or prognostication in ovarian cancer have been found using proteomics. We speculate that it would be interesting to investigate the tissue proteome in an attempt to overcome acute phase reactants and to facilitate the discovery of real tumor-specific biomarkers instead of the identification of secondary protein changes. PMID: 19811810 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2009 Category: Cancer & Oncology Authors: Cadron I, Van Gorp T, Timmerman D, Amant F, Waelkens E, Vergote I Tags: Gynecol Oncol Source Type: journals

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Sunitinib fails to achieve sufficient objective response or sustained disease stabilization as second- or third-line treatment for uterine leiomyosarcoma. PMID: 19811811 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2009 Category: Cancer & Oncology Authors: Hensley ML, Sill MW, Scribner DR, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA Tags: Gynecol Oncol Source Type: journals

Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: SHetA2, but not cisplatin or paclitaxel, can overcome resistance of ovarian cancer cells to TNFalpha and TRAIL without increasing sensitivity of normal cells to these death receptor ligands. PMID: 19804900 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 2, 2009 Category: Cancer & Oncology Authors: Moxley KM, Chengedza S, Mangiaracina D Tags: Gynecol Oncol Source Type: journals

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy. PMID: 19804901 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 2, 2009 Category: Cancer & Oncology Authors: Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O'Malley DM Tags: Gynecol Oncol Source Type: journals

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Pemetrexed has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested. PMID: 19804902 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 2, 2009 Category: Cancer & Oncology Authors: Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN Tags: Gynecol Oncol Source Type: journals

Assessment of sentinel nodes for gynecologic malignancies by natural orifices transluminal endoscopic surgery (NOTES): Preliminary report.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: In this study, we confirmed the feasibility of the SLN technique by NOTES. It can be considered as a potential alternative to reduce morbidity during staging procedures for gynecologic malignancies. Prospective randomized series are necessary to establish the safety and the real benefits of this new technique. PMID: 19801166 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 1, 2009 Category: Cancer & Oncology Authors: Bourdel N, Kondo W, Botchorishvili R, Poincloux L, Niro J, Rabischong B, Jardon K, Pouly JL, Mage G, Canis M Tags: Gynecol Oncol Source Type: journals

Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Using a MS based proteomics approach we have shown that expression of CD70 is associated with cisplatin resistance in ovarian cancer cell lines. Follow-up examination of these tumor cell line findings in clinical tumor specimens with available pathology staging and cisplatin treatment history is warranted. PMID: 19800108 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 30, 2009 Category: Cancer & Oncology Authors: Aggarwal S, He T, Fitzhugh W, Rosenthal K, Feild B, Heidbrink J, Mesmer D, Ruben SM, Moore PA Tags: Gynecol Oncol Source Type: journals

Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: Results of a three-arm Phase I study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: FDR gemcitabine+carboplatin on a 21-day schedule was active and produced no unusual safety signals in patients with Pt-S OC. PMID: 19800673 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 30, 2009 Category: Cancer & Oncology Authors: Alvarez RD, Mannel R, García AA, Gallion HH, Lucci J, Kilgore LC, Numnum TM, Zou SX, Orlando M, Tai DF Tags: Gynecol Oncol Source Type: journals

The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Thus, hospital type did not influence the outcomes of first-line chemotherapy in ovarian cancer patients. However, overall survival was better in hospitals with 2 or more medical oncologists and in hospitals with a high ovarian cancer patient-volume, suggesting differences in second-line chemotherapy. PMID: 19800674 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 30, 2009 Category: Cancer & Oncology Authors: Vernooij F, Witteveen PO, Verweij E, van der Graaf Y, Heintz AP Tags: Gynecol Oncol Source Type: journals

Forwards through the rear-view mirror.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19716938 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 2, 2009 Category: Cancer & Oncology Authors: Russell AH Tags: Gynecol Oncol Source Type: journals

American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19716939 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 2, 2009 Category: Cancer & Oncology Authors: Temin S, Tags: Gynecol Oncol Source Type: journals

Can we improve the detection of glandular cervical lesions: the role and limitations of the Pap smear diagnosis atypical glandular cells (AGC).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19647129 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 5, 2009 Category: Cancer & Oncology Authors: Duska LR Tags: Gynecol Oncol Source Type: journals

Advanced cytoreductive surgery in gynecologic oncology.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19573698 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Bristow RE Tags: Gynecol Oncol Source Type: journals

Surgical program building in advanced ovarian cancer: European perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The majority of ovarian cancer patients are diagnosed with advanced-stage disease, for which standard treatment consists of cytoreductive surgery and platinum-based chemotherapy. As the maximum diameter of residual disease at the end of cytoreductive surgery is one of the most important prognostic factors, chances to achieve complete debulking of tumor should be optimized. Therefore, cytoreductive surgery is best performed in an expert center. To establish such an expert center, not only surgical skills and experience are needed. High quality surgical care is delivered by a multidisciplinary team of, among others, onco...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Verleye L, Ottevanger PB, Vergote I Tags: Gynecol Oncol Source Type: journals

Advanced cytoreductive surgery: Asia Pacific perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The thoroughness of cytoreductive surgery is the largest contributor to survival for patients with advanced ovarian and primary peritoneal carcinoma. For many years the surgery undertaken by Gynaecologic Oncologists has been tailored to match their surgical training. Future surgical training of Gynaecologic Oncologists needs to be tailored to the surgery required to provide complete tumour removal to no residual disease. This means the better teaching of anatomy and an increased scope of surgery to include the general and upper abdominal procedures and management required. This paradigm shift will be a challenge for al...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Crandon AJ, Obermair A Tags: Gynecol Oncol Source Type: journals

Minimally invasive surgery in gynecologic oncology.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19573701 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Magrina JF Tags: Gynecol Oncol Source Type: journals

Emergence of robotic assisted surgery in gynecologic oncology: American perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Robotic surgery is gaining acceptance and is rapidly growing as evidenced by an increased number of publications on the topic; these publications demonstrate the safety, efficacy, and improved outcomes compared to open surgery and conventional laparoscopy. PMID: 19573702 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Mendivil A, Holloway RW, Boggess JF Tags: Gynecol Oncol Source Type: journals

Advanced cytoreductive surgery: American perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article will focus on the role and program development of advanced cytoreductive surgery in patients with gynecologic peritoneal malignancies. This review is an attempt to provide guidance for the rationale and strategic approach to develop the surgical skill set, meet institutional requirements, and implement the concept of a comprehensive cytoreductive surgical team. PMID: 19573703 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Zivanovic O, Aldini A, Carlson JW, Chi DS Tags: Gynecol Oncol Source Type: journals

Indications and teaching of fertility preservation in the surgical management of gynecologic malignancies: European perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Young women affected by a malignant tumor have to cope, after the announcement of diagnosis, with the treatment and its secondary effects. Indeed, some of them may definitively impact on their fertility potential. Especially in pelvic tumors, treatments are more or less mutilating, either by a direct surgical resection of pelvic organs or by destruction of their functioning after chemotherapy or radiation therapy. Surgeons are often at the front line in the management of gynecologic tumors. It is important for them to be aware not only of the surgical techniques currently available to preserve fertility, but as well of...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Leblanc E, Narducci F, Ferron G, Querleu D Tags: Gynecol Oncol Source Type: journals

A model program for radical hysterectomy for cervical cancer: Asia Pacific perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Laparoscopic surgery for gynecological oncology is an important progress in the combination of scientific, technological and surgical techniques, which not only enhanced the efficacy of surgical treatment of gynecological oncology, but also is superior to conventional open surgery with regard to postoperative mental rehabilitation in gynecological oncology patients. But it is not without its risks and complications. There are still several new challenges on both theory and surgical skill improvement to be overcome. Firstly, to form a laparoscopic surgical team, there are a lot of special requirements of both the team m...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Liang Z, Chen G, Xu H, Chen Y, Wang D Tags: Gynecol Oncol Source Type: journals

Surgical education for gynecologic oncologists.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19573706 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Goff BA Tags: Gynecol Oncol Source Type: journals

Surgical education and training program development for gynecologic oncology: American perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The purpose of this paper is to provide information about gynecologic oncology fellowship training and guidance in program development. The characteristics necessary for a physician to develop into a successful gynecologic oncologist include an extensive fund of knowledge related to the subspecialty, strong interpersonal skills, the ability to practice within the complex systems required for management of gynecologic cancer patients, surgical expertise, and the clinical ability to provide comprehensive oncologic care for these women. In order for a trainee to acquire these skills, a gynecologic oncology training progra...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Hoffman MS, Bodurka DC Tags: Gynecol Oncol Source Type: journals

Surgical education and training in gynecologic oncology I: European perspective.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Post-graduate training in oncogynecological surgery should be based on a comprehensive system with three main components: training centers, trainers and trainees. For each of these components, clearly defined requirements should be established. An international consensus on classification, terminology, and performance of standard procedures in gynecological oncology would further improve postgraduate training. One of the key features of this system should be continuous assessment of surgical and non-surgical skills that would make possible the evaluation of individual trainees' progress, as well as the quality of train...
Source: Gynecologic Oncology - July 16, 2009 Category: Cancer & Oncology Authors: Cibula D, Kesic V Tags: Gynecol Oncol Source Type: journals

Cervical cancer state-of-the-clinical-science meeting on pretreatment evaluation and prognostic factors, September 27-28, 2007: proceedings and recommendations.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DISCUSSION: Our current specimen collections are inadequate for discovery and validation of biomarkers. Current and future trials should mandate collection of fixed tissues as well as DNA/RNA. Effective crossgroup collaboration is necessary to permit timely completion of phase III trials. Centers with appropriate expertise and resources in the developing world should be encouraged to participate in the current clinical trial networks. PMID: 19572417 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 7, 2009 Category: Cancer & Oncology Authors: Trimble EL Tags: Gynecol Oncol Source Type: journals

Single-port laparoscopic surgery: Is a single incision the next frontier in minimally invasive gynecologic surgery?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19559942 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 1, 2009 Category: Cancer & Oncology Authors: Ramirez PT Tags: Gynecol Oncol Source Type: journals

"Gynecol Oncol"[ta]; +114 new citationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
114 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: "Gynecol Oncol"[ta] These pubmed results were generated on 2009/06/27PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 27, 2009 Category: Cancer & Oncology Tags: Report Source Type: journals

When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19309637 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2009 Category: Cancer & Oncology Authors: Monk BJ, Ali S, Gaffney DK Tags: Gynecol Oncol Source Type: journals

Hereditary breast and ovarian cancer syndrome.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Authors: PMID: 19309638 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2009 Category: Cancer & Oncology Tags: Gynecol Oncol Source Type: journals

Uterine smooth muscle tumor of uncertain malignant potential: A retrospective analysis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Our results suggest that in this cohort of patients with uterine STUMP the recurrence rate was 7%. Recurrences can be in the form of STUMP or leiomyosarcoma. PMID: 19342083 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2009 Category: Cancer & Oncology Authors: Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A Tags: Gynecol Oncol Source Type: journals

Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Both resveratrol and EGCG induced significant reductions in the amount of VEGF secreted into the supernatant of cultured endometrial cancer cells. These results suggest that resveratrol and EGCG may have the potential to inhibit angiogenesis in endometrial tumours. Further investigation of these substances in endometrial cancer is warranted. PMID: 19321194 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2009 Category: Cancer & Oncology Authors: Dann JM, Sykes PH, Mason DR, Evans JJ Tags: Gynecol Oncol Source Type: journals

E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Our findings suggest that the up-regulation of E-cadherin is an early defining event in ovarian cancer and may play a significant role in the initial development of the primary ovarian tumor. E-cadherin also appears to be important in the development of secondary tumors within the peritoneal cavity. Our data suggest that E-cadherin may prove to be an important target in the preventative treatment of metastatic ovarian cancer and further confirm that the laying hen is a good model for the study of human epithelial ovarian carcinoma. PMID: 19321195 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2009 Category: Cancer & Oncology Authors: Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM, Hales DB Tags: Gynecol Oncol Source Type: journals

A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen. PMID: 19307014 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 21, 2009 Category: Cancer & Oncology Authors: Gupta D, Owers RL, Kim M, Kuo DY, Huang GS, Shahabi S, Goldberg GL, Einstein MH Tags: Gynecol Oncol Source Type: journals

Extragastrointestinal stromal tumor arising in the rectovaginal septum: Report of an unusual case with literature review.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The clinical features and treatment of EGIST are not well known because few cases have been reported. Pathologically, immunohistochemistry with antibody against c-kit protein (CD117) is valuable for diagnosis of EGIST. Mitotic rate is the most reliable prognostic factor, and mutations in KIT may be a clinically useful adjunct marker in the evaluation. Surgery is the most effective treatment, and long-term follow-up is necessary. PMID: 19297012 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 16, 2009 Category: Cancer & Oncology Authors: Zhang W, Peng Z, Xu L Tags: Gynecol Oncol Source Type: journals

A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Patients who underwent the SLN-procedure report less treatment related morbidity compared to those who underwent inguinofemoral lymphadenectomy. However, this did not influence overall quality of life. Furthermore, patients who underwent inguinofemoral lymphadenectomy are more reserved in advising the SLN-procedure to relatives. PMID: 19297013 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 16, 2009 Category: Cancer & Oncology Authors: Oonk MH, van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG Tags: Gynecol Oncol Source Type: journals

Routine follow-up intervals in patients with high-grade squamous intraepithelial lesions (HSIL) and free excision margins can safely be increased in the first two years after Large Loop Excision of the Transformation Zone (LLETZ).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Compliance to the Dutch national routine follow-up protocol in HSIL patients after LLETZ is only moderate. For HSIL patients with free excision margins after LLETZ the first cytological follow-up interval can safely be increased to 12 months. PMID: 19297014 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 16, 2009 Category: Cancer & Oncology Authors: Eijsink JJ, de Bock GH, Kuiper JL, Reesink-Peters N, van Hemel BM, Hollema H, Nijman HW, Mourits MJ, van der Zee AG Tags: Gynecol Oncol Source Type: journals

Dissection of soft-preserved cadavers in the training of gynaecological oncologists: Report of the first UK workshop.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The surgical anatomy knowledge of subspecialty trainees was weak but improved as a result of the dissection course. The most positive finding was the course evaluation. Postgraduate surgical training in GO would likely be enhanced by, and arguably requires, cadaveric dissection. "Soft-preserved" rather than formalin-fixed cadavers should be used. PMID: 19282022 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 10, 2009 Category: Cancer & Oncology Authors: Barton DP, Davies DC, Mahadevan V, Dennis L, Adib T, Mudan S, Sohaib A, Ellis H Tags: Gynecol Oncol Source Type: journals